Literature DB >> 33904894

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

Emily F Mason1, Olga Pozdnyakova2, Mikhail Roshal3, Amir T Fathi4, Eytan M Stein5, P Brent Ferrell6, Aaron C Shaver1, Mark Frattini7, Hongfang Wang8, Lei Hua8, Jimmy Mu8, Sung Choe8, Rengyi Xu8, Caroline Almon8, Michael Cooper8, Richard M Stone9, Robert P Hasserjian10, Michael R Savona6,11,12.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33904894      PMCID: PMC8095142          DOI: 10.1182/bloodadvances.2020003685

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  11 in total

1.  Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

Authors:  Christine M McMahon; Jonathan Canaani; Bryan Rea; Rachel L Sargent; Julianne N Qualtieri; Christopher D Watt; Jennifer J D Morrissette; Martin Carroll; Alexander E Perl
Journal:  Blood Adv       Date:  2019-05-28

2.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.

Authors:  Ghulam J Mufti; John M Bennett; Jean Goasguen; Barbara J Bain; Irith Baumann; Richard Brunning; Mario Cazzola; Pierre Fenaux; Ulrich Germing; Eva Hellström-Lindberg; Itsuro Jinnai; Atsushi Manabe; Akira Matsuda; Charlotte M Niemeyer; Guillermo Sanz; Masao Tomonaga; Teresa Vallespi; Ayami Yoshimi
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941

4.  Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

Authors:  Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Gail J Roboz; Jessica K Altman; Alice S Mims; Ronan Swords; Robert H Collins; Gabriel N Mannis; Daniel A Pollyea; Will Donnellan; Amir T Fathi; Arnaud Pigneux; Harry P Erba; Gabrielle T Prince; Anthony S Stein; Geoffrey L Uy; James M Foran; Elie Traer; Robert K Stuart; Martha L Arellano; James L Slack; Mikkael A Sekeres; Christophe Willekens; Sung Choe; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Hua Yang; David Dai; Bin Fan; Meredith Goldwasser; Hua Liu; Sam Agresta; Bin Wu; Eyal C Attar; Martin S Tallman; Richard M Stone; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2018-06-02       Impact factor: 91.245

5.  Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.

Authors:  Courtney D DiNardo; Farhad Ravandi; Sam Agresta; Marina Konopleva; Koichi Takahashi; Tapan Kadia; Mark Routbort; Keyur P Patel; Sherry Pierce; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2015-08       Impact factor: 13.265

6.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

7.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Authors:  Michael D Amatangelo; Lynn Quek; Alan Shih; Eytan M Stein; Mikhail Roshal; Muriel D David; Benoit Marteyn; Noushin Rahnamay Farnoud; Stephane de Botton; Olivier A Bernard; Bin Wu; Katharine E Yen; Martin S Tallman; Elli Papaemmanuil; Virginie Penard-Lacronique; Anjan Thakurta; Paresh Vyas; Ross L Levine
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Authors:  Eytan M Stein; Courtney D DiNardo; Amir T Fathi; Daniel A Pollyea; Richard M Stone; Jessica K Altman; Gail J Roboz; Manish R Patel; Robert Collins; Ian W Flinn; Mikkael A Sekeres; Anthony S Stein; Hagop M Kantarjian; Ross L Levine; Paresh Vyas; Kyle J MacBeth; Alessandra Tosolini; Jason VanOostendorp; Qiang Xu; Ira Gupta; Thomas Lila; Alberto Risueno; Katharine E Yen; Bin Wu; Eyal C Attar; Martin S Tallman; Stéphane de Botton
Journal:  Blood       Date:  2018-12-03       Impact factor: 25.476

10.  Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Authors:  Eytan M Stein; Courtney D DiNardo; Amir T Fathi; Alice S Mims; Keith W Pratz; Michael R Savona; Anthony S Stein; Richard M Stone; Eric S Winer; Christopher S Seet; Hartmut Döhner; Daniel A Pollyea; James K McCloskey; Olatoyosi Odenike; Bob Löwenberg; Gert J Ossenkoppele; Prapti A Patel; Mikhail Roshal; Mark G Frattini; Frederik Lersch; Aleksandra Franovic; Salah Nabhan; Bin Fan; Sung Choe; Hongfang Wang; Bin Wu; Lei Hua; Caroline Almon; Michael Cooper; Hagop M Kantarjian; Martin S Tallman
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

View more
  1 in total

1.  Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.

Authors:  Adrianne Rasche; Emily F Mason; Stephen A Strickland; Michael Byrne; P Brent Ferrell
Journal:  Br J Haematol       Date:  2021-06-07       Impact factor: 8.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.